A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic and/or unresectable. 2) Documented wild-type in KRAS and NRAS (codons 12, 13, 59, 61, 117, and 146) and in BRAF codon 600, based on tumor tissue taken from primary or metastatic site prior to anti-EGFR antibody treatment. 3) Clinical or radiographic progression on prior anti-EGFR antibody therapy (either panitumumab or cetuximab).

You may not be eligible for this study if the following are true:

  • 1) Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg. Cytokines or antibodies) within 3 weeks of first dose of study treatment. 2) Not recovered to baseline or CTCAE = Grade 1 from adverse events due to all prior anti-cancer therapies except alopecia, oxaliplatin-related neuropathy, and other non-clinically significant adverse events. 3) Any other investigational agents within 21 days before the first dose of study treatment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.